Welcome to our dedicated page for Treatment.com AI news (Ticker: TREIF), a resource for investors and traders seeking the latest updates and insights on Treatment.com AI stock.
Rocket Doctor AI Inc. reports developments in physician-built, AI-powered healthcare technology, including its Rocket Doctor Inc. digital health platform and marketplace and the Global Library of Medicine clinical decision support system. Company news commonly covers virtual and hybrid care services, payer network participation, Medicaid, Medicare and commercial insurance access, rural and municipal care partnerships, connected medical-device distribution, secure patient-clinician communications, and product innovation.
Updates also include corporate governance items such as annual meeting materials, financing activity involving special warrants and prospectus supplements, and market-expansion initiatives in Canada and the United States.
Treatment.com AI (CSE: TRUE, OTC: TREIF) and its virtual care platform, Rocket Doctor, have received recognition from three prestigious healthcare innovation organizations. The company was selected for UC Berkeley's Health Engine non-dilutive accelerator program for high-impact healthcare startups. At Harvard University, CEO Dr. William Cherniak was invited to speak about Rocket Doctor's transformation of healthcare delivery through virtual care, AI, and connected devices. Additionally, at the AARP AgeTech Conference, Dr. Cherniak presented the company's approach to improving care for Medicaid and Medicare patients.
These recognitions follow Rocket Doctor's recent award as Clinical Innovator of the Year at the American Telemedicine Association's NEXUS 2025 Innovators Challenge. The company focuses on using technology to reduce barriers to care and streamline access for underserved populations.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) announced that its virtual care subsidiary, Rocket Doctor, has partnered with Melanoma Canada to provide follow-up care for patients identified as at-risk during mobile skin cancer screenings. The partnership will facilitate direct referrals to Rocket Doctor physicians through a digital intake process for patients without family doctors across Ontario, Alberta, and British Columbia.
The collaboration involves Melanoma Canada's Mole Mobile units, which offer free skin cancer screenings in remote and urban communities. The initiative addresses a critical healthcare need, as skin cancer represents 1 in 3 cancer diagnoses in Canada, with 22 Canadians diagnosed with melanoma daily. The 12-month agreement, starting February 3, 2025, includes branding opportunities on Mole Mobile vans and campaign materials.
Treatment.com AI (TREIF) has signed a Collaborative Agreement with Beijing Aiyi Botong Information Technology (Aiyibotong) to explore commercial opportunities for Clinical Decision Support Systems (CDSS) in China and Far East markets. The partnership aims to combine Treatment's Global Library of Medicine (GLM) with Aiyibotong's CDSS technology.
Key highlights:
- China's CDSS market expected to reach ~US$600 million by 2030
- Aiyibotong has installations in over 200 healthcare institutions in China
- Digital Health investment in China projected to hit US$45 billion in 2025
The collaboration focuses on:
- GLM content localization and alignment with Chinese medical consensus
- Technology licensing and CDSS platform integration
- Co-marketing initiatives in China
- Development of AI-based CDSS for the global market
Treatment.com AI (TREIF) has signed a Collaborative Agreement with Beijing Aiyi Botong Information Technology (Aiyibotong) to explore commercial opportunities for Clinical Decision Support Systems (CDSS) in China and Far East markets. The partnership aims to combine Treatment's Global Library of Medicine (GLM) with Aiyibotong's CDSS technology.
Key highlights:
- China's CDSS market expected to reach ~US$600 million by 2030
- Aiyibotong has installations in over 200 healthcare institutions in China
- Digital Health investment in China projected to hit US$45 billion in 2025
The collaboration includes GLM content localization, technology licensing, co-marketing initiatives, and joint development of AI-based CDSS for the global market. The agreement was signed on February 19, 2025, with no associated costs.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) announces significant growth of Rocket Doctor's virtual healthcare platform in Alberta. The platform has served over 71,000 Albertans, with 35% from communities under 25,000 population.
Key achievements include:
- 112% increase in patient visits year-over-year, serving 36,779 patients
- 218% growth in new physicians joining the platform, with 48 new doctors onboard
- 4.4-star Google rating from over 2,400 reviews
Rocket Doctor's model enables independent physicians to operate efficiently while covered under Alberta's provincial health insurance. The company plans to integrate AI-driven tools and expand its services across Canada. Treatment.com AI Inc. has a definitive share purchase agreement dated February 11, 2025, to acquire Rocket Doctor Inc.